NASDAQ · NPCE

Neuropace, Inc.

$14.81 +$0.13 (+0.89%) 1D Market open
Charting by TradingView

Key Metrics

$504.93M
Market cap
—
P/E · TTM
$99.53M
Revenue · TTM
−$21.57M
Net income
EPS · TTM $-0.69
Dividend yield —
Free cash flow −$9.84M
Beta · 1Y 1.30
EBITDA · TTM −$16.51M
Gross margin 78.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 11
    The stock moved -14.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$504.93M
Enterprise value$509.97M
Shares outstanding34.1M
52-wk range$7.56 – $19.60
Avg volume · 20D122.2K
Net cash −$5.04M
Book value / share$0.46
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Neuropace, Inc.
IPO dateApr 22, 2021
Employees220

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S5.07
P/FCF—
EV/EBITDA—
EV/Sales5.12
Graham №—

Profitability

Gross 78.3%
Operating -16.8%
Net -21.7%
FCF -9.9%
ROE / ROIC -192.0% · —

Financial Health

Current ratio5.38
Quick ratio4.35
Debt / equity4.08
Debt / EBITDA -3.57
Net cash −$5.04M
Working capital$70.81M

Cash Flow · TTM

Operating CF −$9.42M
Capex −$412.00K
Free cash flow −$9.84M
Buybacks $0
Dividends paid —
Shareholder yield 0.0%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

-3.0
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings